Each study has a usefulness score out of 100 (rubric version 4.0). Tap a score to see what makes it up.
Download bibliography of all 5,413 studies, highest score first: BibTeX (.bib) · RIS (.ris)
Highest usefulness score first. Studies without a score come last.
-
To investigate the effect and mechanism of etomidate on attenuating Alzheimer-like neuropathology and cognitive impairment in mice with Alzheimer's disease (AD).
Why it matters
In APP/PS1 mice and in hippocampal neuron cells, etomidate improved memory and spatial learning and reduced amyloid-beta deposition, neuron and synaptic loss, and regulated neuroinflammation and neurotransmitters. This is an animal and cell study, so it does not establish that etomidate treats Alzheimer's disease in people.
-
For persons with early-stage sympathetic Alzheimer's disease (AD), including those with mild cognitive impairment and mild congitive dementia stages of the disease with confirmed amyloid pathology, KISUNLA (donanemab-azbt) is a disease-modifying treatment.
Why it matters
Kisunla (donanemab-azbt) is described as a disease-modifying treatment for people with early-stage Alzheimer disease with confirmed amyloid pathology, and nearly half of research participants finished treatment within a year. The text claims extremely significant results but provides no specific outcome data.
-
Eine von 5 Frauen und einer von 10 Männern entwickeln eine Demenz vom Alzheimer-Typ, erläutern Palmqvist et al. zu Beginn ihrer Studie [1].
Why it matters
A Swedish group presents a blood test combining percentage phosphorylated tau217 and the Aβ42/Aβ40 ratio (APS2) for Alzheimer's disease. This is a diagnostic approach; the text does not report any treatment, cure, or prevention.
-
Studies in Jalisco have identified a mutation in the PSEN1 gene, associated with early-onset Alzheimer's. This variant, common in the Altos de Jalisco region, affects both men and women, causing severe symptoms such as difficulty walking and speaking.
Why it matters
This article describes a PSEN1 gene mutation found in the Altos de Jalisco region of Mexico that is associated with early-onset Alzheimer's, causing severe symptoms, faster progression and shorter life expectancy, and has spread through migration. It calls for continued research into its clinical impact and for counseling programs, but reports no treatment or cure.
-
Evercare recently rolled out its Medicare Advantage special needs plan designed specifically for people with chronic disease and dementia.
Why it matters
This item describes a Medicare Advantage special needs plan for people with chronic disease and dementia. It reports no research on treating, curing, or preventing Alzheimer's disease.
-
Dementia is seen earlier and more often in patients with Down syndrome (DS) than in the general population.
Why it matters
This review notes that dementia appears earlier and more often in people with Down syndrome, who develop brain changes similar to Alzheimer's type. It states that treatable causes of dementia should be ruled out before diagnosing Alzheimer's, but reports no treatment or cure.
-
It has been reported that the Down syndrome occurs more often than expected among relatives of individuals with Alzheimer disease.
Why it matters
Among 578 liveborn offspring of 206 women with Alzheimer's disease, the frequency of Down syndrome births was as expected after controlling for maternal age. This does not support an increased occurrence of Down syndrome in the offspring of women with Alzheimer's disease.
-
Progressive neurodegenerative disorder i.e. Alzheimer’s disease (AD) is characterized by cognitive decline, oxidative stress, and cholinergic dysfunction, β-amyloid aggregation, tau hyperphosphorylation.
Why it matters
This review describes four medicinal plants whose compounds are reported to act through antioxidant, anti-inflammatory, cholinergic and anti-amyloid/tau mechanisms relevant to Alzheimer's disease. It is a summary of reported plant properties and does not provide clinical trial evidence that these plants treat, cure or prevent the disease in people.
-
La enfermedad de Alzheimer (EA) fue descrita por primera vez en una mujer, Augusta D, cuyo caso reveló las características neuropatológicas clásicas de placas amiloides y ovillos neurofibrilares.
Why it matters
This review discusses why Alzheimer's disease affects women more than men, citing factors such as greater longevity, hormonal influences, APOE4, and social determinants, while noting these do not fully explain the difference. It also describes a case in Colombia where homozygous APOE3 Christchurch delayed dementia for decades despite a PSEN1-E280A mutation, but no treatment or cure is presented.
-
Als blutbasierter Biomarker zur Diagnose der Alzheimer-Krankheit gilt p-Tau217.
Why it matters
The MEMENTO and BALTAZAR studies examined whether the accuracy and predictive value of blood p-tau217 vary between cognitive phenotypes in patients without dementia. This is about interpreting a diagnostic biomarker, not about treating, curing, or preventing Alzheimer's disease.
-
Wissenschaftler*innen der Washington Universität in St. Louis untersuchten in dieser aktuellen Studie Machbarkeit und Sicherheit der Therapie mit dem monoklonalen Antikörper Lecanemab bei Patientinnen und Patienten mit früher symptomatischer Alzheimer-Krankheit.
Why it matters
Researchers at Washington University in St. Louis examined the feasibility and safety of lecanemab in patients with early symptomatic Alzheimer disease. The available text gives no further results on treating, curing or preventing the disease.
-
A doença de Alzheimer (DA) configura-se como a principal causa de demência em idosos, se tornando um dos maiores desafios da medicina moderna devido à sua alta prevalência e o impacto social associado.
Why it matters
This integrative review analyzes studies on the tau protein as a biomarker for early diagnosis and monitoring of Alzheimer's disease. It is about diagnosis and monitoring, not treatment, and does not demonstrate any cure or prevention.
-
Mit der Zulassung von Lecanemab in Europa ist die Antikörpertherapie bei Alzheimer Krankheit (AD) hierzulande angekommen.
Why it matters
With the approval of lecanemab in Europe and donanemab in the USA, antibody therapy for Alzheimer's disease has arrived, but these new options have generally not been compared directly in studies. Network meta-analyses are proposed to help weigh the effectiveness of these new agents against each other.
-
Eine Möglichkeit zur Behandlung von beginnenden Alzheimer-Erkrankungen stellten Anti-Amyloid-Antikörper (AK) dar, die die Amyloidablagerungen im Gehirn reduzieren sollen.
Why it matters
This report describes refractory status epilepticus during treatment with anti-amyloid antibodies, noting that therapies targeting Alzheimer-typical changes can cause serious side effects. Although these are rare, failure to recognize them can be fatal, and the authors call for longitudinal MRI studies to identify possible high-risk groups.
-
25/100
This survey presents 50 research papers focussed on various techniques in Alzheimer classification techniques using 3D MRI images, and the categorisation of the techniques is made based on the fusion-based, convolutional neural network (CNN)-based, random forest (RF)-based and support vector machine (SVM)-based approaches.
Why it matters
This survey reviewed 50 research papers on techniques for classifying Alzheimer's disease using 3D MRI images. It identifies research gaps and issues in these classification methods rather than reporting a new treatment or cure.
-
25/100
-
We have reported recently the sublocalization of an Alzheimer Disease-associated gene that encodes for cerebrovascular beta-amyloid protein (BAP).
Why it matters
This early laboratory study found that a beta-amyloid protein probe hybridized to chromosome 9 in three people with familial Alzheimer's disease but not in normal or Down syndrome individuals. The authors state further studies are needed to determine whether this is a genetic marker, so it has no current treatment or prevention meaning.
-
First, family members bear witness to the behavioral debility, memory decline, and loss of expression associated with Alzheimer disease.
Why it matters
This piece notes that family members witness the behavioral decline, memory loss, and loss of expression in Alzheimer's disease. It offers no information on treating, curing, or preventing the disease.
-
The objective of a new report, ‘European Dementia Monitor 2017: comparing and benchmarking national dementia strategies and policies’, is to provide a benchmark of national dementia policies in order to compare the responses of European countries to the dementia challenge in different domains.
Why it matters
This report benchmarks national dementia policies across Europe to compare countries' responses to the dementia challenge. It is about access to dementia care and treatment, not about curing or preventing Alzheimer's disease.
-
Alzheimer's disease and related dementias are known to affect both the patient and the family caregiver.
Why it matters
This paper describes the creation of a Medicare Advantage plan for people with Alzheimer's disease and related dementias that includes specialized clinical care and support for family caregivers. It does not test a treatment, cure, or prevention for Alzheimer's disease.
-
GWAS found associations between plasma biomarkers and the APOE gene.
-
Symptomatic DIAD participants who had been treated for ∼ 4 years with anti-Aβ monoclonal antibodies (gantenerumab, n=4 or solanezumab, n=4) were compared with untreated, symptomatic DIAD mutation carriers (n=40) and with age-relevant non-DIAD controls with modest or no plaque pathology (n=18).
-
MTD showed excellent discrimination of CU versus MCI/DEM (AUC=.89; 95% CI=.87-.92), and discriminability remained high for CU versus MCI (AUC=.88; 95% CI=.85-.92).
Why it matters
A remote, self-administered digital cognitive test detected mild cognitive impairment and mild dementia with strong accuracy, and performed similarly to established in-person tests for distinguishing biomarker groups. This could help make cognitive testing more widely available, but it is a diagnostic tool and does not treat or prevent Alzheimer's.
-
NST showed stable cross-cohort structure (Mantel r = 0.71-0.77) and differentiated MCI (d = -0.39) and AD biomarker status (d = -0.23).
Why it matters
This study developed a speech-based measure that distinguished people with mild cognitive impairment and Alzheimer's biomarker status, and tracked cognitive change over time. It also showed smaller disparities by race and education than standard cognitive tests, but it is a measurement tool, not a treatment.
-
Cellular mechanisms in early Alzheimers disease (AD) remain poorly understood despite generation of extensive observational multiomic data.
Why it matters
This analysis of existing genomic data pointed to mitochondrial electron transport chain dysfunction and Wnt signalling as shared pathways in early Alzheimer's disease across several brain cell types. It also identified existing drugs like guanfacine and new candidates like eltrombopag and encorafenib that could be investigated further, but no treatments were tested in patients.
From across this topic
10 of the 5,374 studies in this topic, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
- Blood Phosphorylated Tau 181 as a Biomarker for Amyloid Burden on Brain PET in Cognitively Healthy Adults
- Tau PET in Alzheimer disease and mild cognitive impairment
- Prediction of Alzheimer disease in subjects with amnestic and nonamnestic MCI
- Molecular abnormalities of the brain in Down syndrome: relevance to Alzheimer's neurodegeneration
- Neuropsychiatric symptoms in Alzheimer's continuum and their association with plasma biomarkers
- Characterizing risk and protective factors for Alzheimer's disease and related dementias in American Samoa
- Association between Hypothyroidism Onset and Alzheimer Disease Onset in Adults with Down Syndrome
- APOE3 Christchurch Heterozygosity and Autosomal Dominant Alzheimer's Disease
- Incidence of Amyloid-Related Imaging Abnormalities in Phase III Clinical Trials of Anti-Amyloid-β Immunotherapy: An Updated Meta-Analysis
- Evaluation of the safety and immunogenicity of synthetic Abeta42 (AN1792) in patients with AD